Browsing Tag
efimosfermin
2 posts
GSK trades near 2,027p as Q1 core EPS rises 9%, full-year 2026 guidance reaffirmed
GSK beat the top line and held guidance, but the harder question is whether Specialty Medicines can keep outrunning the Vaccines and General Medicines drag.
April 29, 2026
GSK to acquire efimosfermin from Boston Pharmaceuticals for $2bn to bolster liver disease pipeline
GSK acquires Phase III-ready efimosfermin from Boston Pharmaceuticals for $2B, expanding its liver disease pipeline with a fibrosis-reversing specialty drug.
May 14, 2025